Inclusive of all taxes
ZOP 7.5 TAB BLUE F/C - Dr Precision is a premium pharmaceutical-grade blue film-coated tablet containing 7.5 mg of Zopiclone, specifically formulated for the short-term management of insomnia. This non-benzodiazepine hypnotic acts on the central nervous system by enhancing GABAergic neurotransmission via selective binding to the benzodiazepine site of the GABA-A receptor complex, promoting rapid sleep onset, increased sleep duration, and reduced nocturnal awakenings. Its blue film coating not only ensures easy visual identification but also provides protection from moisture and light, enhancing shelf-life stability and patient compliance. Manufactured under GMP, ISO, and WHO-compliant pharmaceutical-grade conditions by Dr Precision and distributed through BluepillExpress, this tablet guarantees consistent quality, precise formulation, and effective bioavailability. Ideal for adults experiencing transient or situational insomnia, it supports sleep initiation typically within 30 minutes post-ingestion and is designed for use under medical supervision for short durations (7-10 days). The formulation is suited for customization in packaging and branding for both domestic and international B2B markets. ZOP 7.5 offers superior benefits over traditional benzodiazepines with a shorter half-life, minimizing next-day sedation and abuse potential, making it a preferred choice among healthcare professionals for safe and effective insomnia management.
Key Features
| Features | Description |
|---|---|
| Active Ingredient | Zopiclone 7.5 mg |
| Tablet Type | Blue Film-Coated (F/C) Tablet |
| Indication | Short-term treatment of insomnia |
| Mechanism of Action | Selective binding to benzodiazepine site on GABA-A receptor enhancing GABAergic neurotransmission |
| Onset of Action | Typically within 30 minutes |
| Packaging Options | Blister packs or strip packaging customizable for private labeling |
| Manufacturing Standards | GMP, ISO, and WHO-compliant pharmaceutical-grade production |
| Shelf Life Benefits | Film coating protects from moisture and light, enhancing stability |
| Recommended Duration | 7 to 10 days under medical supervision |
| Attributes | Description |
|---|---|
| Dosage Strength | 7.5 mg Zopiclone per tablet |
| Formulation Type | Non-benzodiazepine hypnotic, cyclopyrrolone derivative |
| Tablet Color | Blue |
| Pharmacokinetics | Short half-life, rapid absorption, minimal next-day sedation |
| Indications | Difficulty falling asleep, frequent nocturnal awakenings, early morning arousals |
| Contraindications | Hypersensitivity to Zopiclone, severe respiratory insufficiency, sleep apnea, myasthenia gravis |
| Side Effects | Dry mouth, metallic taste, drowsiness, dizziness, rare complex sleep behaviors |
| Target Consumers | Adult patients with short-term insomnia |
| Packaging | Customizable blister and strip packs for B2B supply |
| Manufacturing Compliance | GMP certified, ISO standards, WHO guidelines |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
ZOP 7.5 contains Zopiclone, a non-benzodiazepine hypnotic with a shorter half-life and fewer residual sedative effects, reducing the risk of next-day drowsiness and dependence compared to traditional benzodiazepines.
The blue film coating protects the active ingredient from moisture and light, enhancing the tablet’s shelf-life stability, improving patient compliance through easy identification, and ensuring rapid disintegration for faster onset.
No, ZOP 7.5 is intended only for short-term use, typically 7 to 10 days, to avoid risks of dependency, withdrawal symptoms, and rebound insomnia. It must be used under strict medical supervision.
Yes, ZOP 7.5 tablets are available in customizable blister or strip packaging, suitable for private labeling and compliant with regulatory requirements across domestic and international markets.
Prescribers should caution patients to allocate 7-8 hours for uninterrupted sleep to avoid residual sedation, monitor for possible side effects such as complex sleep behaviors, and avoid use in patients with contraindications like severe respiratory insufficiency or sleep apnea.
ZOP 7.5 selectively binds to the benzodiazepine site on the GABA-A receptor complex, enhancing inhibitory GABAergic neurotransmission which induces sedation, anxiolysis, and muscle relaxation, thus promoting faster sleep initiation.
Country Of Origin: India
ZOP 7.5 Tablet is a blue, film-coated formulation containing 7.5 mg of Zopiclone. Designed for short-term treatment of insomnia, it promotes quicker sleep onset, longer sleep duration, and reduced nighttime awakenings. Manufactured under strict quality standards, it is a reliable and effective solution for transient or situational sleep disturbances.
This product is manufactured under the Dr Precision label, ensuring GMP-compliant quality and precision formulation standards.
ZOP 7.5 Tablet is a pharmaceutical-grade product formulated with Zopiclone 7.5 mg, presented as a blue film-coated (F/C) tablet for enhanced visual identification and patient compliance. Zopiclone is a cyclopyrrolone derivative classified as a non-benzodiazepine hypnotic agent that acts on the central nervous system to induce sleep. It enhances GABAergic neurotransmission through selective binding to the benzodiazepine site of the GABA-A receptor complex, leading to sedative, anxiolytic, and muscle-relaxant effects.
ZOP 7.5 is specially indicated for the short-term management of insomnia, particularly in patients who experience difficulty in falling asleep, frequent nocturnal awakenings, or early morning arousals. The blue film-coated tablet is designed for rapid disintegration and absorption, ensuring the onset of sleep typically within 30 minutes of ingestion. It is ideal for adults requiring quick symptomatic relief from stress-related or transient insomnia.
The blue F/C design of the tablet ensures protection from moisture and light while offering better shelf-life stability and patient acceptability. The formulation complies with GMP, ISO, and WHO standards, manufactured under pharmaceutical-grade facilities suitable for both domestic and export markets. It is available for third-party manufacturing and private label branding through BluepillExpress, ensuring reliability, scalability, and market-specific customization in dosage packaging and presentation.
ZOP 7.5 is generally well-tolerated when used as directed. It is recommended for short durations only, typically 7 to 10 days, and always under strict medical guidance to avoid dependency, withdrawal, or rebound insomnia. Patients using ZOP 7.5 should ensure they can dedicate at least 7 to 8 hours of uninterrupted rest to prevent residual sedation or impaired alertness the following day. The pharmacokinetic profile supports its use in both men and women without significant accumulation in the system when used appropriately.
The therapeutic action of Zopiclone does not alter the normal architecture of sleep but works to restore a healthy sleep pattern disrupted by stress, environmental changes, or medical conditions. It is a preferred choice over benzodiazepines due to its short half-life, lesser hangover effect, and lower abuse potential. Nonetheless, prescribers must exercise caution in elderly individuals, patients with hepatic or renal impairment, and those concurrently using CNS depressants.
ZOP 7.5 Tablet may cause side effects such as dry mouth, bitter or metallic taste, drowsiness, and dizziness in some individuals. Rarely, it may be associated with complex sleep behaviors like sleepwalking or sleep-driving, especially when combined with alcohol or other sedatives. As such, patient education and physician monitoring are essential during therapy. The drug is contraindicated in individuals with hypersensitivity to Zopiclone, severe respiratory insufficiency, sleep apnea syndrome, or myasthenia gravis.
In global markets, Zopiclone 7.5 mg remains one of the most widely prescribed agents for short-term insomnia management. ZOP 7.5 by BluepillExpress is produced with strict adherence to international pharmacopoeial guidelines, ensuring accurate dosing, uniformity, and bioavailability. It is available in blister packs or strip packaging, customizable based on client requirements for branding and regulatory compliance in local or export markets.
Healthcare providers and distributors alike prefer ZOP 7.5 Tablet for its dependable clinical outcomes, ease of use, and the quality assurance that comes from BluepillExpress' state-of-the-art facilities. As the demand for safe and effective sleep aids increases across the globe, ZOP 7.5 stands as a trusted solution that combines efficacy, safety, and convenience in one well-designed dosage form.
Inclusive of all taxes
You Save: 0
Surat , India
Manufacturer, Contractor, Retailer, Brand Owner, Distributor, Exporter, Importer, Wholesaler, Startup
GST- 24abdfb4194j1ze